Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edaravone/(+)-2-nonanol - Beijing Tiantan Hospital/Yantai Yene Pharma

Next Previous
Drug Profile

Edaravone/(+)-2-nonanol - Beijing Tiantan Hospital/Yantai Yene Pharma

Alternative Names: (+)-2-nonanol/edaravone; adaravone and borneol sublingual tablet; Y 2; Y-2 sublingual tablets

Latest Information Update: 02 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Tian Tan Hospital; YenePharma
  • Developer YenePharma
  • Class Anti-inflammatories; Antihaemorrhagics
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke
  • No development reported Haemorrhage

Most Recent Events

  • 05 Dec 2023 Simcere Pharmaceutical completes a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA (NCT05940883)
  • 06 Sep 2023 Simcere Pharmaceutical initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA (NCT05940883)
  • 11 Jul 2023 Simcere Pharmaceutical plans a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA, in July 2023 (NCT05940883)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top